Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2019-10-22 Regulatory Filings
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Positive results presented at UEG Week 2019
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement from the London Stock Exchange's news service (RNS). The content details the presentation of positive clinical trial results (Phase 3b AEGIS-H2H study) for the product Feraccru®/Accrufer™ at a medical conference (UEG Week 2019). This is an announcement of scientific/clinical data presentation, not a full financial report (like 10-K or IR), a formal earnings release (ER), or a management discussion (MDA). Since it is a specific announcement disseminated via the RNS system, and it doesn't fit the definitions for DIV, DIRS, MANG, or CT, the most appropriate classification is the general regulatory announcement category, RNS, as it is explicitly branded as an RNS filing.
2019-10-22 English
Investor Presentation
Investor Presentation Classification · 98% confidence The document is identified by the RNS Number (6891N) and the date (26 September 2019), indicating it is a regulatory announcement from the London Stock Exchange. The content explicitly states that Shield Therapeutics plc "announces that the Company will be hosting an investor presentation on Tuesday 12 November 2019." It details the time, location, and contact information for registration. Crucially, it states, "No new material information will be disclosed at this event and the presentation will be made available on the Company's website." This structure—announcing a future event (like a presentation) without providing the presentation material itself—fits the definition of an Investor Presentation (IP) announcement, but since the document's primary function is to disseminate this specific scheduling information via the regulatory news service (RNS), and it is not the presentation itself, it aligns best with the Investor Presentation (IP) category, as it is specifically about an upcoming investor presentation. If it were just a generic announcement, RNS would be the fallback, but IP is more specific to the content type being announced.
2019-09-26 English
Hardman & Co Research: Shield Therapeutics (STX): FDA approval ushers in a new era for Shield
Regulatory Filings Classification · 99% confidence The document is a short announcement (3788 characters) from 'Hardman & Co Research' regarding Shield Therapeutics (STX). It summarizes key news (FDA approval) and explicitly states, 'Please click here for the full report:'. This structure—a brief summary followed by a link to the complete document—fits the definition of a Report Publication Announcement (RPA), as per the 'MENU VS MEAL' rule. It is not the full research report itself, but the announcement of its availability.
2019-09-02 English
Investor presentations
Report Publication Announcement Classification · 99% confidence The document is a formal announcement disseminated via RNS (RNS Number : 4608K), which is the news service of the London Stock Exchange. The content explicitly states that the company, Shield Therapeutics plc, "announces that the Company will be presenting at the following investor forums." It details two upcoming events: the Hardman/LSE Life Sciences Forum and the Proactive One2One Investor Forum, including dates, times, and contact information for registration. This type of announcement, informing investors about upcoming presentations or roadshows, aligns perfectly with the definition of an Investor Presentation (IP) announcement, or more generally, a communication about investor engagement. Since the document is announcing participation in investor forums where presentations will be given, the most specific and appropriate code is 'IP' (Investor Presentation). It is not the presentation itself, but the announcement of it, which often falls under IP or RPA/RNS. Given the specific mention of 'Investor presentations' in the body, 'IP' is the best fit, as it relates directly to the content being shared at those events.
2019-08-29 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly mentions 'RNS Number : 1839J' and 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a transaction involving a director/PDMR (James Karis, Chairman) acquiring shares, which falls under insider trading or director's dealing notification requirements under MAR (Market Abuse Regulation). The specific category for director share transactions is 'Director's Dealing' (DIRS). Although it is an RNS announcement, DIRS is a more specific classification than the general RNS fallback.
2019-08-15 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report for the six months ended 30 June 2019' and contains detailed financial highlights, operational reviews, and unaudited financial results for the specified period. It is a comprehensive report rather than a brief announcement, fitting the definition of an Interim/Quarterly Report. H1 2019
2019-08-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.